BACKGROUND: Neuroimmune activation in the spinal dorsal horn plays an important role in the pathogenesis of chronic pain after peripheral nerve injury. OBJECTIVE: The aim of this study was to examine the role of neuroimmune activation in below-level neuropathic pain after traumatic spinal cord injury (SCI). METHODS: Right hemilateral SCI was created in male Sprague-Dawley rats by controlled blunt impact through a T12 laminectomy. Pain-related behaviors were assessed using both evoked reflex responses and an operant conflict-avoidance test. Neuroimmune activation was blocked by the anti-inflammatory cytokine interleukin-10 (IL-10) delivered by a nonreplicating herpes simplex virus (HSV)-based gene transfer vector (vIL10). Markers of neuroimmune activation were assessed using immunohistochemistry and Western blot. RESULTS: One week after SCI, injured animals demonstrated mechanical allodynia, thermal hyperalgesia, and mechanical hyperalgesia in the hind limbs below the level of injury. Animals inoculated with vIL10 had a statistically significant reduction in all of these measures compared to injured rats or injured rats inoculated with control vector. Conflict-avoidance behavior of injured rats inoculated with vIL10 was consistent with significantly reduced pain compared with injured rats injected with control vector. These behavioral results correlated with a significant decrease in spinal tumor necrosis factor α (mTNFα) expression assessed by Western blot and astrocyte activation assessed by glial fibrillary acidic protein immunohistochemistry. CONCLUSION: Below-level pain after SCI is characterized by neuroimmune activation (increase mTNFα and astrocyte activation). Blunting of the neuroimmune response by HSV-mediated delivery of IL-10 reduced pain-related behaviors, and may represent a potential novel therapeutic agent.
BACKGROUND: Neuroimmune activation in the spinal dorsal horn plays an important role in the pathogenesis of chronic pain after peripheral nerve injury. OBJECTIVE: The aim of this study was to examine the role of neuroimmune activation in below-level neuropathic pain after traumatic spinal cord injury (SCI). METHODS: Right hemilateral SCI was created in male Sprague-Dawley rats by controlled blunt impact through a T12 laminectomy. Pain-related behaviors were assessed using both evoked reflex responses and an operant conflict-avoidance test. Neuroimmune activation was blocked by the anti-inflammatory cytokine interleukin-10 (IL-10) delivered by a nonreplicating herpes simplex virus (HSV)-based gene transfer vector (vIL10). Markers of neuroimmune activation were assessed using immunohistochemistry and Western blot. RESULTS: One week after SCI, injured animals demonstrated mechanical allodynia, thermal hyperalgesia, and mechanical hyperalgesia in the hind limbs below the level of injury. Animals inoculated with vIL10 had a statistically significant reduction in all of these measures compared to injured rats or injured rats inoculated with control vector. Conflict-avoidance behavior of injured rats inoculated with vIL10 was consistent with significantly reduced pain compared with injured rats injected with control vector. These behavioral results correlated with a significant decrease in spinal tumor necrosis factor α (mTNFα) expression assessed by Western blot and astrocyte activation assessed by glial fibrillary acidic protein immunohistochemistry. CONCLUSION: Below-level pain after SCI is characterized by neuroimmune activation (increase mTNFα and astrocyte activation). Blunting of the neuroimmune response by HSV-mediated delivery of IL-10 reduced pain-related behaviors, and may represent a potential novel therapeutic agent.
Authors: E D Milligan; K A O'Connor; K T Nguyen; C B Armstrong; C Twining; R P Gaykema; A Holguin; D Martin; S F Maier; L R Watkins Journal: J Neurosci Date: 2001-04-15 Impact factor: 6.167
Authors: J R Bethea; H Nagashima; M C Acosta; C Briceno; F Gomez; A E Marcillo; K Loor; J Green; W D Dietrich Journal: J Neurotrauma Date: 1999-10 Impact factor: 5.269
Authors: Annemarie Ledeboer; Evan M Sloane; Erin D Milligan; Matthew G Frank; John H Mahony; Steven F Maier; Linda R Watkins Journal: Pain Date: 2005-05 Impact factor: 6.961
Authors: David J Fink; James Wechuck; Marina Mata; Joseph C Glorioso; James Goss; David Krisky; Darren Wolfe Journal: Ann Neurol Date: 2011-07-27 Impact factor: 10.422
Authors: Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso Journal: Nat Rev Neurol Date: 2013-04-23 Impact factor: 42.937
Authors: Soha J Chhaya; Daniel Quiros-Molina; Alessandra D Tamashiro-Orrego; John D Houlé; Megan Ryan Detloff Journal: J Neurotrauma Date: 2018-10-18 Impact factor: 5.269
Authors: Ryan B Griggs; Renee R Donahue; Braxton G Adkins; Katie L Anderson; Olivier Thibault; Bradley K Taylor Journal: J Pain Date: 2015-12-12 Impact factor: 5.820
Authors: Wenwen Zheng; Wan Huang; Shue Liu; Roy C Levitt; Keith A Candiotti; David A Lubarsky; Shuanglin Hao Journal: Anesth Analg Date: 2014-09 Impact factor: 5.108
Authors: Morgana D da Silva; Franciane Bobinski; Karina L Sato; Sandra J Kolker; Kathleen A Sluka; Adair R S Santos Journal: Mol Neurobiol Date: 2014-06-25 Impact factor: 5.590
Authors: Qing Yang; Zizhen Wu; Julia K Hadden; Max A Odem; Yan Zuo; Robyn J Crook; Jeffrey A Frost; Edgar T Walters Journal: J Neurosci Date: 2014-08-06 Impact factor: 6.167